Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as cystic fibrosis bronchiectasis. This is a lung disease where the airways become damaged, leading to symptoms like persistent cough and frequent lung infections. The trial will test a new treatment called BI 1291583, which is taken as a tablet once a day. The study will compare the effects of this treatment to a placebo, which looks like the real medication but does not contain any active ingredients.

The purpose of the study is to see how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants will take the medication or placebo for 12 weeks. During this time, researchers will monitor the participants to see if they experience any side effects and how their bodies process the medication. The study will also involve the use of salbutamol sulfate, a common medication used to help open the airways in the lungs, which will be administered through inhalation.

Throughout the study, participants will have regular check-ups to ensure their safety and to gather information on how the treatment is working. The trial aims to provide valuable insights into the safety and effectiveness of BI 1291583 for treating cystic fibrosis bronchiectasis, potentially leading to better treatment options for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and conducting necessary tests to ensure the patient meets the criteria for participation.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either the BI 1291583 tablet or a placebo. This process is double-blind, meaning neither the patient nor the researchers know which treatment is being administered.

  3. Step 3

    Treatment phase

    The treatment phase lasts for 12 weeks. During this period, patients take one tablet of BI 1291583 5 mg or a placebo once daily by mouth.

    In addition to the tablet, patients may use salbutamol sulfate as needed for inhalation to manage symptoms.

  4. Step 4

    Monitoring and assessments

    Throughout the trial, regular monitoring and assessments are conducted to evaluate safety and effectiveness. This includes checking for any side effects and measuring changes in lung function and other health indicators.

    At week 8, a specific assessment is conducted to measure changes in neutrophil elastase activity in sputum.

  5. Step 5

    Follow-up

    After completing the 12-week treatment phase, patients undergo a follow-up period lasting up to 16 weeks from the first drug administration. This includes additional assessments to monitor any ongoing effects of the treatment.

Who can join the trial?

7 criteria

  • Patients must be at least 18 years old when they sign the informed consent form.
  • Patients need to have a past clinical diagnosis of cystic fibrosis (CF), which is a genetic condition affecting the lungs and other organs. This diagnosis is confirmed by symptoms and a sweat test showing chloride levels of 60 mmol/L or higher, or by having two CF-causing gene mutations.
  • Patients must have a diagnosis of bronchiectasis (BE), which is a lung condition that causes coughing and mucus production. This diagnosis should be confirmed by a CT scan and a clinical history that matches BE symptoms. If past CT scans are not available, a new scan will be done during the screening. Past scans should not be older than 5 years.
  • Patients should have a history of lung flare-ups, known as pulmonary exacerbations, that required antibiotic treatment. In the year before the first visit, patients must have had either at least two flare-ups or at least one flare-up and a St. George's Respiratory Questionnaire (SGRQ) Symptoms score of more than 40 at the first screening visit. For those on stable antibiotics for BE, at least one flare-up must have happened while on these antibiotics.
  • Patients must be able to provide samples of mucus from their lungs, either naturally or through a process called induced sputum.
  • Patients must sign and date a written informed consent form, following international guidelines and local laws, before joining the trial.
  • Both male and female patients can participate. Women who can have children must agree to use highly effective birth control methods that have a failure rate of less than 1% per year, along with one barrier method. Men must use male contraception, like condoms or abstain from sex, if their partner is a woman who can have children.

Who cannot join the trial?

4 criteria

  • Patients who do not have cystic fibrosis bronchiectasis cannot participate. This is a lung condition where the airways become damaged and widened.
  • Patients who are not within the specified age range cannot participate. The age range includes children and adults.
  • Both male and female patients are considered for participation, so gender is not an exclusion factor.
  • Patients who are part of a vulnerable population may not be eligible. A vulnerable population includes groups like children, pregnant women, or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

BI 1291583 is a medication being tested in this clinical trial. It is taken as one tablet once daily for 12 weeks. The trial aims to evaluate its safety and how well it is tolerated by patients with cystic fibrosis bronchiectasis. The study also looks at how the body processes the medication and its effects on the body.

What is already known about the treatment

BI 1291583 – This medication is administered in tablet form and is taken once daily. It is currently being studied in clinical trials to assess its safety, tolerability, and effects in patients with cystic fibrosis bronchiectasis. The main therapeutic indication for BI 1291583 is to manage symptoms associated with cystic fibrosis bronchiectasis. At the molecular level, it works by targeting specific pathways involved in the disease process, although the exact mechanism is still under investigation. It is classified pharmacologically as an investigational drug, as it is still undergoing research to determine its efficacy and safety profile.

Investigated diseases

Cystic Fibrosis Bronchiectasis – Cystic fibrosis bronchiectasis is a condition where the airways in the lungs become damaged and widened due to the thick, sticky mucus associated with cystic fibrosis. This mucus can lead to repeated lung infections and blockages, causing inflammation and further damage to the airways. Over time, the airways lose their ability to clear mucus effectively, leading to persistent cough, difficulty breathing, and frequent respiratory infections. The disease progresses as the cycle of infection and inflammation continues, causing more damage to the lung tissue. Patients may experience symptoms such as chronic cough, production of sputum, and shortness of breath. The condition is considered a rare disease and requires ongoing management to help control symptoms and prevent complications.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-502835-21-00Protocol code1397-0013Estimated enrolment25 patientsSponsorBoehringer Ingelheim Espana S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.